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Abstract
Substantial evidence suggests that serotonin (5-HT) activation within the brain modulates
anxiety-like behavior. The bed nucleus of the stria terminalis (BNST) has been argued to
mediate anxiety-like behavioral responding, and the activation of 5-HT systems may
modulate anxiety-like behavior via the release of 5-HT within the BNST. Prior studies
have suggested that the 5-HT1, 7 agonist 5-carboxyamidotrytamine (5-CT) is anxiolytic,
which is consistent with a reduction in BNST activity via the activation of postsynaptic 5HT1A receptors. However the anxiolytic effects of 5-CT could also have been mediated
by 5-HT7 receptor activation. Hence, to isolate the effects of 5-HT1A on anxiety-like
behavior, we infused the 5-HT1A antagonist WAY-100635 (0, 0.04, 0.4, and 4.0 µg/µl in
saline vehicle) into the BNST of rats immediately before social interaction or acoustic
startle testing. For social interaction testing pairs of rats were administered two 5-sec 1mA footshocks immediately after infusion, removed from the chamber and measured for
social interaction in a separate testing apparatus. For acoustic startle testing, rats were
placed in boxes and measured for the percentage increase in test (post-infusion) startle
from baseline (pre-infusion) startle. Anxiety levels were operationalized as the amount
of social interaction per line cross and the percentage increase in startle following drug
infusion. WAY-100635 dose dependently decreased social interaction, indicative of an
anxiogenic effect. Interestingly, 0.4µg/µl of WAY-100635 decreased startle, indicative
of an anxiolytic effect. These data suggest that activation of the 5-HT systems modulates
anxiety-like behavior by altering activity within the BNST.
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Introduction
Anxiety is the most prevalent of all psychological disorders in America, affecting
over 40 million people annually (DuPont et al., 1998). Anxiety disorders include panic
disorder, obsessive compulsive disorder, generalized anxiety disorder, and phobic
disorder. While the symptoms that underlie these clinical disorders are well
characterized, the brain mechanisms that produce anxiety in humans and animals are less
clear. Anxiety has been described as a fear response that persists over an extended period
of time even if a threat is not immediately present (Walker, Toufexis, & Davis, 2003).
For example, a normal adaptive fear response includes the set of behaviors activated in
the face of a threat, as in the case of a person walking through the woods who encounters
a bear. An individual with an anxiety disorder will exhibit this same fear response too
intensely or at an inappropriate time. Due to the time course and lack of specificity of
anxiety, disorders involving anxiety represent a maladaptive response that interferes with
the everyday functioning of an individual’s life. Although anxiety disorders afflict
human populations, many experimental manipulations needed to understand the
mechanisms that underlie anxiety-like behaviors cannot be performed on human subjects.
By using animal models, these questions can be explored through the ability to control
and utilize various manipulations that may influence anxiety-like behavior.
Behavioral Paradigms
The neurobiology of anxiety has been extensively studied, however, is still not
well understood. The mechanisms argued to mediate anxiety-like behavioral states are
numerous and involve various neurochemicals and brain areas. Researchers that study
animal models of anxiety have designed a multitude of behavioral paradigms that have
1

been argued to quantify varying anxiety levels. The acoustic startle response is a
common behavior utilized to measure the emotional state of an animal through
measurement of the natural reflexive action to jump (startle) in response to a loud noise
burst. An underlying anxiety-like state has been argued to mediate some increases in
startle responding; although, other manipulations can increase startle without affecting
anxiety. For example, serotonin injected onto the spinal cord increases the amplitude of
the startle reflex and without having any influence on affect (Davis, Astrachan,
Gendelman, & Gendelman, 1980). In order to determine whether an experimental
manipulation, such as a pharmacological treatment or stressor exposure modulates
anxiety, comparisons are often made between the startle amplitude exhibited prior to the
manipulation (baseline) and those exhibited after the manipulation. An anxiogenic
(anxiety producing) response is assumed if the rat demonstrates elevated startle levels
after the manipulation when compared to baseline; whereas lower startle levels in
comparison to baseline are indicative of an anxiolytic (anxiety reducing) effect (for
review, see Davis, 1989). To ensure that these changes in startle amplitude are reflective
of changes in affect rather than changes in motor activity, multiple behaviors are often
measured.
The acoustic startle response is a reflexive response that can be modulated in
anxiety-provoking situations, however, animals can also be tested for varying levels of
anxiety through placement into an approach-avoidance conflict situation (Handley,
1995), such as social interaction testing. Social interaction in rodents is an ecological
behavior used in the study of anxiety and has been demonstrated in natural settings (File
& Pallab, 2003). Using the social interaction behavioral paradigm developed by File
2

(1978), an experimenter pairs rodents that are naïve to each other, and measures the
amount of time the pair interacts; including sniffing, following, boxing, fighting or
grooming. An anxiolytic response to an experimental manipulation would be suggested
if rats spend longer amounts of time in social interaction in comparison to control treated
rats (File & Hyde, 1978). While acoustic startle and social interaction are used in many
experiments examining anxiety, anxiety is often characterized by a coordinated complex
set of behavioral responses that are not limited to those just described.
Brain and Behavioral Correlates
An expansive area of research has been devoted to examining the specific brain
mechanisms associated with changes in anxiety behaviors in humans and anxiety-like
behaviors in animal species. Most of the circuitry associated with the modulation of
maladaptive anxiety-like behaviors is the same as those that are important in modulation
of behaviors associated with an adaptive fear response. For example, fear conditioning
procedures, in which a neutral stimulus (conditioned stimulus) is paired with an aversive
or noxious stimulus (unconditioned stimulus) so that the conditioned stimulus (CS)
comes to elicit a fear response (Ledoux, 1998), have implicated subregions of the
amygdala in the acquisition and expression of these responses.
The lateral and basolateral amygdala (LA/BLA) are brain regions where sensory
information is assigned an affective valence, and relayed to the central amygdala (CeA)
and bed nucleus of the stria terminalis (BNST), which coordinate behavioral responding
(LeDoux, Cicchetti, Xagoraris, & Romanski, 1990; LeDoux, Farb, & Ruggiero, 1990;
Davis, 1992; Walker et al., 2003; Shammah-Lagnado, Alheid, & Heimer, 2001). The
CeA and BNST share a similar developmental history, which leads to similar
3

morphology, chemoarchitecture and physiology (Alheid, de Olmos, & Beltramino, 1995).
The CeA and BNST also both project to areas that are responsible for coordination of
specific responses to stress such as those previously described (Walker et al., 2003). For
example, the BNST and CeA both coordinate similar anxiety/fear-like behavioral
responses such as increased startle and freezing through projections to the nucleus
reticularis pontis caudalis (Davis, 1989) and periaquiductal grey as well as decreases in
social interaction via the central grey (for review, see Walker et al., 2003). This suggests
that the CeA and BNST might play a major role in the expression and acquisition of
conditioned fear (Davis, 1992).
Outcomes from behavioral studies have led Davis and colleagues (2003) to
suggest that there may be a differentiation between the role of the CeA and BNST in
mediating adaptive fear responding versus the maladaptive responding that characterizes
anxiety disorders in humans. Extensive research has examined the role of the BNST
within anxiety-like behavior in animal models through lesion, pharmacological and
immunohistochemical techniques (Walker & Davis, 2002; Davis, 1998; Duncan, Knapp,
& Breese, 1996; Hammack, Richey, Watkins, & Maier, 2004). For rats, presentation of a
startle eliciting noise burst in the context of bright light causes elevations in startle in
comparison to noise burst presentation in dimly lit arenas, which has been called light
enhanced startle and is BNST-mediated (Walker & Davis, 2002). Lesions made to the
BNST with the glutamate antagonist 2, 3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinozaline-2, 3-dione (NBQX) block the expression of light enhanced startle;
however, lesions of the central nucleus of the amygdala have no effect on startle (Walker
& Davis, 1997). Interestingly, light-enhanced startle in rodents is analogous to dark4

enhanced startle observed in humans; a person that is placed within a dark room will
show elevated startle to a noise burst in comparison to a startle eliciting noise burst
within a brightly lit room (Grillon, Pellowski, Merikangas, & Davis, 1997).
Several other anxiety-like behaviors are mediated by the BNST. For example, the
BNST also mediates fear-like responding to long-duration conditioned stimuli (Waddell,
Morris, & Bouton, 2006). In this, a 10-minute tone or 1-minute tone was paired with a
foot-shock and rats were measured for the amount of suppressed bar presses which had
been previously paired with receiving food. Lesions made to the BNST blocked the
expression of conditioned suppression to the 10-minute tone but not to the 1-minute tone
(Waddell et al., 2006), and previous studies have shown that the CeA mediates fear
conditioning to short duration conditioned stimuli (Fendt & Fanselow, 1999)
During a paradigm called learned helplessness, the lack of control over stress can
produce a pathological anxiety-like state which has been argued to model anxiety
disorders in humans (Maier & Watkins, 2005). Helpless animals exhibit exaggerated fear
conditioning and decreases in social interaction, (Maier et al., 1993; Short & Maier,
1993; Short, Patel, Lee, Talarico, 2000). BNST lesions made prior to learned
helplessness treatment blocked the anxiogenic behavioral consequences normally
produced by exposure to uncontrollable stress (Hammack et al., 2004). The behaviors
associated with learned helplessness are mediated by increases in serotonin (5-HT)
activity, and reducing 5-HT activity attenuates learned helplessness behaviors (Maier et
al., 1993). Hence these studies suggest that increased serotonergic release within the
BNST may mediate behaviors associated with learned helplessness.
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The BNST contains some of the highest levels of extrahypothalamic
corticotropin-releasing hormone (CRF) found in the central nervous system (CNS).
Increases in CNS CRF activity is anxiogenic, and has been shown to elevate startle
levels. Lee and Davis (1997) found that neurotoxic lesions of the BNST but not the
amygdala blocked the enhanced startle responding observed after intracerebroventricular
(ICV) CRF. Moreover, rats administered local infusions of CRF into the BNST
demonstrated enhanced startle whereas rats administered local CRF infusions into the
amygdala did not (Lee & Davis, 1997). Local CRF BNST infusions also decreased the
time spent in open arms in the elevated plus-maze task, consistent with an anxiogenic
effect (Sahuque et al., 2006). This suggests that CRF receptor activation within the
BNST mediates anxiety-like responses through promoting an anxiogenic response.
Studies of neural activation have also provided support for the role of the BNST
in anxiety-like behaviors. Fos, a protein product of the immediate early gene c-Fos, is
expressed when a neuron is excited, and is often used as a marker of neural activation
(Duncan et al., 1996). Systemic administration of anxiogenic pharmacological agents
such as the benzodiazepine inverse agonist FG-7142, the 5-HT2A receptor agonist
mCPP, the alpha2 adrenergic receptor antagonist yohimbine, or caffeine has led to
increases in Fos activation in the BNST and the CeA (Singewald, Salchner, & Sharp,
2003). This study suggests that both areas may be involved in fear and anxiety circuitry.
However, other studies have demonstrated the activation of the BNST but not the CeA
when animals were exposed to an anxiogenic behavioral treatment. For example, in the
social defeat paradigm, two male rodents are placed within the same cage and one is
allowed to defeat the other. The defeated animal responds with defensive and anxiety6

like behaviors in the presence of any other conspecific (Martinez, Phillips, & Herbert,
1998). Social defeat activated the BNST as compared to Fos-levels in control animals
(Martinez et al., 1998). A similar study demonstrated that repeated exposure to social
defeat within rats resulted in increased Fos expression in the BNST but not in the CeA
thus supporting the hypothesis that the activation of BNST neurons mediates anxietyrelated behaviors (Chung, Martinez, & Herbert, 1999). Finally, using functional
magnetic resonance imaging (fMRI) techniques, Straube et al. (2007) found that humans
who have phobias of spiders exhibited increased activation in the BNST in comparison to
individuals without this phobia while anticipating the presentation of spider-associated
stimuli. (Straube, Mentzel & Miltner, 2007).
Based on these collective data, Davis and colleagues (2003) have proposed that
the CeA and BNST mediate anxiety-like responding to two distinct types of stimuli. The
CeA modulates behaviors to stimuli that are specific and produces behaviors that are
quick in onset and terminate shortly following the removal of the stimuli. However the
BNST modulates behaviors that are “sluggish” to initiate and persist long after the
behavioral eliciting stimuli has been terminated. The stimuli that provoke anxiety- like
behavioral responses are diffuse, non-specific and longer in duration. Although the
distinction between these two areas in their involvement in fear and anxiety-like behavior
is still unclear, the results of previous experiments suggest that malfunctioning of the
BNST is likely to mediate the behavioral expression of some anxiety disorders in
humans.
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Neurochemistry
The specific brain areas that have been argued to modulate anxiety-like and fear
related behavior can be modulated by various neurochemicals. Gamma-aminobutyric
acid (GABA), the major neurotransmitter that mediates inhibition in the brain, is widely
distributed and manipulations of GABAergic systems have been demonstrated to
influence the anxiety/fear- related behavior. For example, benzodiazepines are common
GABA(A) receptor allosteric modulators that increase the efficacy of GABA in opening
GABA(A)-coupled chloride ion channels, and result in enhanced inhibition of neurons by
GABA (Clement & Chapouthier, 1998; Nutt & Malizia, 2001). Benzodiazepine agonists
are anxiolytic, and inhibit brain regions associated with the fear circuitry, such as the
amygdala (Clement & Chapouthier, 1998; Nutt & Malizia, 2001). Additionally, systemic
administration of a GABA receptor agonist in rats resulted in an anxiolytic effect as
measured by the increases in time spent in the open arms of an elevated-plus maze
(Rodgers & Dalvi, 1997). The infusion of benzodiazepines into the BLA resulted in an
anxiolytic effect of increased time spent in social interaction within rats, suggesting that
the BLA may be a site of therapeutic action for this class of drugs (Gonzalez, Andrews,
& File, 1996). The role of GABA within the BNST is discussed below.
Norepinephrine manipulations have also been shown to modulate anxiety-like
behaviors in response to stress (Connor & Davidson, 1998; Morilak et al., 2005).
Norepinephrine antagonists for both the 1- and - receptors injected into the lateral
septum attenuated defensive burying of a shock probe placed within an animal’s cage (for
review, see Morilak et al., 2005). Moreover, blockade of the 1 receptors in the CeA
attenuated anxiogenic effects within social interaction while 1- and - receptor blockade
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in the lateral BNST attenuated anxiogenic effects in the elevated-plus maze (Cecchi,
Khoshbouei, & Morilak, 2002; Cecchi, Khoshbouei, Javors, & Morilak, 2002). Connor
and colleagues (1998) argue that reduced norepinephrine receptor sensensitivity found
within clinical populations with anxiety disorders is due to the chronic high
concentrations of circulating norepinephrine within this population.
As previously discussed, CRF has also been shown to have both direct and
indirect effects in modulating anxiety-like behaviors, including those associated with
learned helplessness Administration of a large dose of intracerebroventricular CRF
increased behaviors associated with learned helplessness when the animals were tested 24
hours later (Ronan, Kramer, Kram, & Petty, 2000). Moreover, the administration of CRF
to rats directly into the serotonergic dorsal raphe nucleus (DRN), a brain area associated
with learned helplessness, produced learned helplessness-like behaviors 24 hours later
(Hammack et al., 2002). The administration of CRF antagonists into the DRN prior to
administration of inescapable shock attenuated the behavioral expression of anxiety-like
behavior (Hammack et al., 2003). Administration of CRF and CRF agonists to rats has
also been found to increase anxiety levels as measured indicated through potentiated
startle (Lee & Davis, 1997). Although systemic and intra-DRN administration of CRF,
and CRF agonists and antagonists have been found to modulate the behavioral expression
of learned helplessness and acoustic startle, these effects might be indirect through
excitation of serotonergic neurons within the DRN (Hammack et al., 2003; Kirby, Rice,
& Valentino, 2000).
While pharmacotherapies have been developed to modulate some of the
previously described neurotransmitters involved in anxiety (i.e. benzodiazepines),
9

currently, the most widely prescribed medication for anxiety disorders are selective
serotonin reuptake inhibitors (SSRIs). SSRIs block the reuptake of endogenously
released 5-HT, causing it to be maintained within the synaptic space for longer periods of
time. The efficacy in this pharmacological agent in the treatment of anxiety disorders
suggests that 5-HT likely modulates anxiety. While some mechanisms through which 5HT activation modulates anxiety-like behavior have been explored, its exact role is still
unclear. Intrinsic 5-HT release (endogenous) and pharmacological manipulations
(exogenous) which can mimic 5-HT, or increase or decrease 5-HT within the brain have
different effects on anxiety depending on the area of neuronal activation and activation of
specific 5-HT receptor subtypes. Furthermore, pharmacological manipulations of
serotonergic effects can also differentially affect anxiety depending on the length of
treatment (Handley, 1995).
Although SSRIs have been shown to be beneficial in the treatment of anxiety,
clinical evidence has demonstrated that patients will often feel more anxious within the
first week of treatment before feeling less anxious following longer treatment. For
example, it has recently been documented that a single dose of 20mg of citalopram, an
SSRI, potentiates the expression of fear and anxiety in the presence of threatening or
aversive stimuli in healthy human participants (Grillon, Levenson, & Pine, 2007).
Within rats, acute treatment with SSRI fluoxetine results in an anxiogenic effect
evidenced through decreased social interaction and increased number of escapes from the
aversive qualities of an airjet (Salchner & Singewald, 2002). The acute versus chronic
SSRI treatment effects have also been demonstrated within animals, with acute treatment
with SSRI citalopram administered systemically to rats enhancing auditory fear
10

conditioning in rats whereas rats treated for 22 days with citalopram demonstrating
decreased freezing when placed in the context previously associated with the receiving
shock (Burghardt, Sullivan, McEwen, Gorman, & LeDoux, 2004).
5-HT release can also have different effects on anxiety behavior depending on
brain region. Disruption of 5-HT release within the amygdala through administration of
5,7-dihydroxytryptamine (5,7-DHT) resulted in an anxiolytic effect on the punished
drinking test, but had no effect on behavior in the elevated-plus maze (Sommer et al.,
2001). These inconsistent results suggest that the two behaviors may be differentially
sensitive to serotonergic activity within the amygdala. An anxiolytic effect was found
after 5,7-DHT lesions made to the median raphe nucleus through increasing time spent in
open arms in the elevated plus maze task if animals had be previously put through a
stressor. This lesion and previous exposure to stress also increased time spent in the
anxiogenic context of a bright compartment when animals were tested in the light-dark
box task in comparison to animals that did not receive the neurotoxic lesion (Andrade &
Graeff, 2001). Other anxiogenic effects have been found following disruption of 5-HT
activity within the septum through increased performance of defensive aggression, escape
behavior and enhanced startle responses (for review see Handley, 1995).
As described above, the activation of 5-HT systems can produce different effects
on anxiety like behavioral responding depending on the length/dosage of serotonergic
administration as well as the brain region in which 5-HT is modulated. However,
confusion regarding the effects of 5-HT activation on behavioral responding is most often
explained by the large number of receptor subtypes to which 5-HT binds. There are over
eighteen different receptor subtypes that bind 5-HT and these receptors can mediate very
11

different effects on neuronal activity, including acute inhibition (hyperpolarization)
and/or excitation (depolarization), and a variety of long term responses (Uphouse, 1997).
That multiple serotonergic receptor subtypes can be located within the same brain area
and on the same cell adds complexity to an already complex system.
5-HT has a similar high affinity for both receptors within the 5-HT1 and 5-HT7
families, and preferentially binds to these receptor subtypes when endogenous 5-HT
levels are low (Palacios, Raurich, Mengod, Hurt, &

s, 1996). The 5-HT1 family is a

G-protein coupled receptor that mediates its activity through reducing adenylyl cyclase
activity and/or opening inwardly rectifying K+ (GIRK) channels resulting in a
hyperpolarizing response which decreases serotonergic release and neuronal firing
(Uphouse, 1997; Lanfumey & Hamon, 2004; Gross, Santarelli, Brunner, Zhuang, & Hen,
2000). The 5-HT2 and 5-HT4 receptors are G-protein coupled but lead to excitatory
responses through a slow membrane depolarization through increasing phospholipase C
and adenylate cyclase, respectively (Uphouse, 1997). The 5-HT3 receptor is the only
receptor that is linked to a ligand-gated cation channel and mediates a fast excitatory
response, but desensitizes rapidly. 5-HT5, 5-HT6 and 5-HT7 receptors are also G-protein
excitatory receptors that are poorly understood in mechanism of action but add to
complexity of understanding the mechanism through which 5-HT modulates behaviors
(Uphouse, 1997).
Long term serotonergic pharmacological treatments, such as SSRIs, most likely
lead to different behavioral effects due to changes in receptor sensitivity following
chronic activation of these receptor subtypes. These adaptations include, but are not
limited to, receptor downregulation, upregulation, and changes in protein cascades
12

(Uphouse, 1997). These adaptations may be one reason behind the change in anxiety
observed across time during SSRI treatment. The previously discussed results suggest
that 5-HT, BNST, and the receptors to which 5-HT binds play some role in the
modulation of anxiety, and the therapeutic effect of SSRI treatment. Therefore, the goal
of the current set of experiments is to further elucidate the role that 5-HT might be have
within the BNST in anxiety.
Anatomy
The BNST is a complex heterogeneous structure with groups of cells that have
different morphology, projection patters and neurochemistry, leading some to divide the
structure into over 30 distinct subregions (Ju & Swanson, 1989; Ju, Swanson, & Simerly,
1989). The anterolateral group, including the oval nucleus, has been most implicated in
anxiety-like responding, in part, due to its afferent and efferent projections and its
neurochemistry. The oval nucleus of the BNST contains two distinct regions: the shell,
which is composed of layers of interneurons, and the core, containing both interneurons
and projection neurons (Larriva-Sahd, 2006). Relatively short projections originating
from the oval nucleus innervate the anterolateral and anterodorsal areas of the BNST
(Dong, Petrovich, Watts & Swanson, 2001a). The oval nucleus region of the BNST is
highly connected with the medial and lateral CeA, receives sparse projections from the
BLA, and also projects to areas that are responsible for coordination or motor movements
such as the paraventricular hypothalamic nucleus (Dong, Petrovich & Swanson, 2001b,
Dong et al., 2001a). The oval nucleus may serve as a connection between the limbic
system (extended amygdala) and motor responses (Larriva-Sahd, 2006). Similarly the
anterolateral BNST is highly connected with the medial, lateral and ventral capsular CeA
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and also highly interconnected with the serotonergic and anxiety-related caudal DRN
(Dong & Swanson, 2004; Vienante, Stoeckel, & Freund-Mercier, 1997; Commons,
Connolley, & Valentino, 2003; Dong et al., 2001a; Cassell, Freedman, & Shi, 1999).
Additionally, electrical stimulation of the lateral BNST alters cardiovascular responses
and has been suggested to play a role in coordination of responses to aversive stimuli
(Dunn & Williams, 1995; Alheid, 2003; Commons et al., 2003).
The anterolateral group of the BNST, which includes the oval nucleus and
anterolateral subregions, contains dense populations of neurons that can co-express
GABA, CRF, enkephalin or neurotensin (Ju et al., 1989; Sun & Cassell, 1993; Vienante
et al., 1997; Phelix, Liposits, & Paul, 1992; Peto, Arias, Vale, & Sawchenko, 1999; Day,
Curran, Watson, & Akil, 1999). However anatomical data suggest that these
neurochemicals may be distributed in different populations of BNST neurons. For
example, there is a consistent lack of co-expression between enkephalin and CRF within
the anterolateral BNST, suggesting that these neuropeptides are expressed by different
BNST cell types. Furthermore, electrophysiological and pharmacological data suggest
that 5-HT receptor subtypes may be differentially distributed on neurons, with colocalization of 5-HT1A, 2A, and 7 receptors on one population of BNST neurons, and
separate distinct populations of BNST neurons that express only the 5-HT1A or 5-HT7
receptor subtypes. Lastly, projections from this BNST region contain neuropeptides
whose release can have either inhibitory or excitatory effects in terminal regions. This
suggests that the circuitry associated with modulation of activity within the BNST is
highly complex. Interestingly, this region, which has been associated with anxiety-like
responding, is targeted by 5-HT projections from the caudal DRN (Commons et al.,
14

2003), which has also been associated with anxiety-like responding (Hammack et al.,
2002).
Physiology
The literature reviewed above suggests that 5-HT may modulate anxiety by
modulating BNST activity. Electrophysiological and immunohistochemical studies have
begun to examine how 5-HT affects neuronal activation within the BNST. As described
earlier, 5-HT can modulate neurons within the BNST as demonstrated by Fos activation
within the BNST following treatments with 5-HT agonists such as mCPP (Singewald et
al., 2003). An earlier study found that systemic injection of 5-HT1A receptor subtype
agonist, flesinoxan, increased Fos within the BNST. Although a 5-HT1A agonist would
be expected to reduce BNST activity, the BNST is densely populated with GABAergic
neurons, therefore interneurons within the BNST normally under inhibition via GABA
would now become active due to disinbitition. Flesinoxan may also attenuate DRN
activity, releasing the BNST from normal serotonin-mediated inhibition. Regardless of
mechanism, the increased Fos activation following flesinoxan suggests that 5-HT can
modulate activation of neurons within the BNST (Compaan, Groenink, van der Gugten,
Maes & Oliver, 1996).
Direct modulation of BNST neuronal activity by 5-HT application has also been
examined. The neuronal responses to various neurotransmitters can be determined using
electrophysiological techniques that measure the intrinsic properties of individual
neurons in vitro. Using whole cell patch clamp techniques, Rainnie (1999a) isolated
specific neurons in the dorsal portion of both the lateral and medial BNST and measured
the response to 5-HT bath application. Within these areas, BNST neurons exhibited
15

multiple responses to 5-HT, such that single neurons could respond to 5-HT with
depolarization, hyperpolarization, hyperpolarization followed by depolarization or no
change in membrane potential (Rainnie, 1999a). As previously discussed, the
anterolateral group of the BNST has been hypothesized to have a critical role in
modulation of responses to stressful stimuli (Alheid, 2003; Commons et al., 2003).
Therefore Levita and colleagues (2004) sought to examine the response of neurons within
this BNST subregion to 5-HT application, extending the findings of Rainnie (1999a), in a
larger sample of neurons. When a 50 M concentration of 5-HT was applied to the cells,
11% of these cells responded with pure hyperpolarization, 25% responded with
depolarization and 45% of these cells had a mixed response of hyperpolarization
followed by depolarization (Levita, Hammack, Mania, Li, Davis & Rainnie, 2004).
The various responses to 5-HT within the BNST are mediated by at least four
different 5-HT receptor subtypes present within the BNST, including 5-HT1A, 2A, C and
7 receptors (Levita et al., 2004; Hammack, Haensly & Rainnie, 2005). The 5-HT1A
receptor mediates all direct neuronal inhibition by 5-HT within the BNST (Levita &
Hammack, 2004) while the 5-HT2A, C and 7 receptors mediate excitation (Hammack,
Mania, & Rainnie, 2005). Because BNST 5-HT1A receptors mediate BNST inhibition,
activation of the 5-HT1A receptors within the BNST should be anxiolytic. The aim of
the current set of studies is to examine the role of this receptor subtype in its modulation
of anxiety-like behaviors.
5-HT1A Receptor Subtype
The activation of the 5-HT1A receptor has been argued to mediate the anxiolytic
effects of serotonin. Mice that lack the 5-HT1A receptor have been shown to avoid
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stressful situations, which is indicative of higher levels of anxiety (Lanfumey & Hamon,
2004). When 5-HT1A knock-out (KO) mice were exposed to foot-shock, they
demonstrated enhanced freezing and increased heart rate in comparison to wild-type
controls (Gross et al., 2000). Studies have also demonstrated increased levels of anxiety
in 5-HT1A KO mice through less time spent in open-arms of the elevated plus maze and
less time spent in the center during the open-field task (Heisler et al., 1998; Parks,
Robinson, Sibille, Shenk & Toth, 1998; Overstreet et al., 2003).
Pharmacological agents that target the 5-HT1A receptor modulate fear/anxietylike behavior. Administration of the 5-HT1A partial agonist buspirone to rats following
training in fear-potentiated startle was sufficient in attenuation of fear-potentiated startle,
although it did not affect baseline startle (Risbrough, Brodkin, & Geyer, 2003). Rats that
were administered 5-HT1A receptor agonist 8-OH-DPAT thirty minutes prior to shock
demonstrated a dose dependent reduction in ultrasonic vocalizations in comparison to
animals that did not receive treatment, again consistent with an anxiolytic behavioral
effect (De Vry, Schreiber, Melon, Dalmus & Jentzsch, 2004). Interestingly, marmoset
monkeys administered systemic injections of the 5-HT1A antagonist WAY-100635
demonstrated decreased anxiety-like behavior when placed in a maze where escape was
only possible through close proximity to a predator, indicative of an anxiogenic action of
5-HT1A activation (Barros et al., 2003). These mixed findings are most likely due to the
fact that systemic drug injection produces non-specific drug effect in multiple regions,
and suggesting that different drugs may have different sites of action.
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Aim of Current Study
While studies are beginning to examine the effects of the 5-HT1A receptor
subtype microinjected into specific areas of the brain, only a few pharmacological
manipulations have examined the role BNST 5-HT1A modulation in the modulation of
anxiety-like behavior. Levita et al. (2004) administered 5-carboxamindotryptamine
(5CT), an agonist that has high affinity for the 5-HT1A, 1B, 1D, 5 and 7 receptor
subtypes, onto BNST slices found that this agonist produced a predominantly inhibitory
response profile using whole-cell patch-clamp electrophysiological techniques.
Consistent with BNST inhibition, intra-BNST injection of 5CT decreased baseline
acoustic startle amplitude in comparison to animals that received vehicle treatment.
These results suggest that activation of the 5-HT1A receptor subtype within the BNST is
anxiolytic (Levita et al., 2004). Although the previous results suggest that activation of
the 5-HT1A mediates anxiolytic responses within the BNST, 5CT could also have its
anxiolytic effects through activation of the 5-HT7 receptor within the BNST.
Preliminary experiments within our lab sought to block this behavioral effect of 5-CT on
baseline startle through concomitant administration of selective 5-HT1A antagonist,
WAY-100635. However, results indicated that the antagonist was having an effect
without concomitant administration of an agonist which suggested that there was
endogenous tonic serotonin release. The current set of experiments sought to better
explore this finding through measurement of social interaction and baseline acoustic
startle in response to various doses of WAY-100635. Adult male Sprague-Dawley rats
received bilateral BNST cannulations, allowed to rest, assigned to drug groups and were
measured for anxiety levels utilizing the above behaviors. Due to the anxiolytic effects
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of agonists at the 5-HT1A receptor subtype within the baseline acoustic startle paradigm,
it is expected that blockade of this receptor subtype within the BNST will promote
anxiogenic effects within both behavioral paradigms.
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Methods
Animals
Male Sprague-Dawley rats (200-275 g) were purchased from Charles River
Laboratories (Wilmington, MA). Rats were singly housed and kept on a 12 hr light/dark
cycle (lights on at 7 AM) with food and water available ad libitum. Animals were given
one week of rest upon arrival to the facility prior to behavioral testing or surgery. All
procedures were approved by the Institutional Animal Care and Use Committee (IACUC)
of the University of Vermont.
Apparatus
Footshock. A conditioning chamber (Med Associates, St Albans, VT) was used
to administer shocks prior to social interaction testing. The 30 x 25 x 35 cm chamber was
constructed out of aluminum and clear polycarbonate and contained a grid floor made up
of twenty stainless steel bars (4.8 mm diameter) that were spaced 16.0 mm apart. The
testing chamber was contained within a larger (65 x 50 x 55 cm) sound attenuating
chamber (Med Associates, St. Albans, VT). Scrambled footshocks were delivered
through the grid floor using a SG500power source (Med Associates, St. Albans, VT)
controlled by Med PC IV software installed on an OptipleX GX240 computer (Dell
Computer Corporation, Round Rock, TX).
Social Interaction. Social interaction testing was conducted in a room with a
brightness of 128 lux within a 55 x 55 cm opaque white plastic box with 50 cm high
walls (United States Plastics Corp., Lima, OH). In order to measure locomotor activity,
the box was divided into smaller squares with horizontal and vertical separations every
11 cm using red tape. An analogue video camera (Panasonic MiniDV, PV-GS35,
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Secaucus, NJ) mounted vertically above the test arena was used to record social
interaction and locomotor activity.
Startle. The four stabilimeter chambers used for startle testing were 15 x 15 x 8
cm wire mesh and Plexiglas boxes that contained a grid floor of four stainless steel bars
(6.0mm in diameter) spaced 18.0mm apart (Med Associates, St. Albans, VT). Each
chamber hung from four springs and rested on a rubber stopper within a 90 x 70 x 70 cm
sound-attenuating chamber. A high frequency speaker (Radio Shack Supertweeter;
Tandy, Fort Worth, TX) located approximately 5 cm away from the back of the startle
chamber delivered the 50-ms white noise burst startle stimuli (5ms rise-decay) created by
a computer sound file (0-22 kHz) and amplified by a Radio Shack Amplifier (100 Watt;
Model MPA-200; Tandy, Fort Worth, TX). Background noise of 60dB was generated
through a random noise generator (General Radio Company; Concord, MA).
The startle response elicited through each noise burst was measured through the
displacement of the accelerometer located at the bottom of the cage. The voltage
produced was proportional to the velocity of displacement, with startle amplitude defined
as the maximal peak-to-peak voltage (displacement) during the first 200-ms after
stimulus onset. The accelerometer output was amplified (PCB Piezotronics, Model
483B21) and digitized by an InstruNET converter (GW Instruments, Model 100B;
Somerville, MA) interfaced to a Macintosh G3 computer.
Surgery
BNST Cannulation. On the day of surgery, rats were weighed and brought into
the surgical suite. Isoflorane was vaporized into oxygen through an Isotec vaporizer
(Fraser Harlake, Orchard Park, NY) which flowed into a plastic chamber in which the
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animal was initially anesthetized. Once anesthetized, the animal was removed from the
chamber and the surgical area was shaved. The subject was then fitted into the
stereotaxic instrument (KOPF Instruments; Tujunda, CA) using blunt ear bars and the
bite bar set to a height of -3.5 mm. Isoflorane was delivered through a nose cone secured
to the bite bar. A heating blanket set at the lowest setting was placed under the animal to
encourage proper circulation during surgery.
Proper aseptic preparation was completed with cleaning of the surgical area with
Bentadine scrub (Purdue Product L.P., Stamford, CT) 3 times followed by a rinse of 70%
ethyl alcohol. A single incision was made on the dorsal surface of the skull with a
scalpel. The skull was exposed and thoroughly cleaned with cotton-tipped applicators
and gauze. Occasionally 0.3 mL hydrogen peroxide (3%) was used in order to clear the
area of blood. Four hemostats were used to pull away the skin at four corners of the
incision area to expose the surface of the skull. Using a 395 Variable Speed MultiPro
Rotary Tool Kit (Dremel) 4 screw holes were through the skull at the outermost corners
of the surgical site. Screws (Small Parts, Miami, FL & PlasticsOne, Roanoke, VA) were
then screwed halfway into the drilled holes in order to stabilize the skull cap.
Both stereotaxic arms were each fitted with a 22 gauge stainless steel guide
cannula that were 2 cm long (PlasticsOne, Roanoke, VA) and attached to the stereotaxic
frame using specially designed holders (PlasticsOne, Roanoke, VA). Guide cannulae
were aimed at the BNST at an angle of 20º in order to avoid placement in the lateral
ventricle. For each side, the tip of the guide cannulae were centered on bregma and
aimed at a site just dorsal to the BNST based on the coordinates of the Paxinos and
Watson brain atlas (1998) (26mm lateral, 3.82 mm posterior to bregma). Once it was
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determined where each guide cannula would enter the skull, a hole was drilled and the
surface of the dura was exposed. Once holes were drilled, guide cannulae were lowered
until the tip touched the dura. Both guide cannulae were aimed 5.3mm ventral to the dura
surface.
Following implantation, guide cannulae were secured to the skull using “cold
cure” denture material and cross linking methyl methacrylate liquid compound (Co-Oralite, Diamond Springs, CA). Dummy cannulae were made from stainless steel wire
(dia.014 in., Small Parts, Miami, FL) and placed into each guide cannula extending
approximately 1 mm beyond cannula tip to prevent clogging. The dummy cannulae were
secured to the skull cap with denture material. After the denture material dried, the
subject was removed from the stereotaxic instrument and administered one subcutaneous
injection of 0.3 ml (.3mg/ml:5 ml sal) of buprenorphine (Hospira, Lake Forest, IL) and
one subcutaneous injection of 1 ml Lactated Ringers Solution. Approximately .1 ml of
Marcaine (Hospira Inc., Lake Forest, IL) was administered dropwise around the incision
site as a topical anesthetic. The subject was allowed to recuperate under a heat lamp and
brought back to colony room upon revival. Two post-operative .3 ml subcutaneous
buprenorphine injections were administered the day following surgery, and postoperative checks were maintained for seven days during the subject’s recuperation as per
IACUC protocol. Rats were allowed to recuperate for one week after surgery before
brain infusion and behavioral testing. During this week, rats were handled every day in
order to perform post operative checks and habituate them to experimental procedures.
Guide Cannulae Placement Verification. On the day of sacrifice the rat was
weighed, brought into the surgical area within their home cage and received an injection
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of 150 mg/kg sodium pentobarbital in 7.8% isopropyl alcohol (Fort Dodge Animal
Health, Fort Dodge, IL). Under deep anesthesia, the rat was removed from its cage and
placed onto a wire mesh covering which rested over a catch bucket.
An incision across the abdomen and below the xiphoid process was made. The
rat received an injection of .2-.3 ml Heparin (Abraxis, Shaumburg, IL) directly through
the diaphragm into the heart to reduce blood coagulation. Cuts were made up both sides
of the lungs and across the diaphragm to allow to access to the heart. One incision was
made to the left ventricle to allow a blunted 14- gauge needle attached to a systolic pump
(Manostat, Barrington, IL) to be inserted into the aorta and another incision was made in
the right atrium. Saline was then pumped through the body. After approximately 30
seconds, 4% Paraformaldehyde or Formalin 10% was pumped through the same system
in order to fix brain tissue. Once sufficiently fixed, the brain was removed and placed in
a vial containing either Paraformaldehyde 4% or Formalin 10% for postfixing for at least
24 hours.
Brains were sectioned (60-90 µm) on either a freezing microtome or cryostat at
-30°C. Slices were stored in phosphate buffered solution and kept refrigerated until
staining. Brain sections were mounted onto chromium aluminum subbed slides and
stained with cresyl violet. Slides were treated with a series of dehydrating washes, cresyl
violet incubation and washing. Following cresyl violet staining, slides were coverslipped
using mounting medium (Richard Allen Scientific; Kalamazoo, MI).
Guide cannulae placement was verified under a light microscope and notes were kept as
to which area the guide cannulae tracts extended.
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Drug Administration
Three doses of WAY-100635 and one vehicle control treatment were used during
the behavioral studies described below. Drug aliquots containing 10.0 l of 8.0 µg
WAY-100635 per 0.5 µl de-ionized water were frozen until needed. On the day of
testing, the aliquots were allowed to thaw and further diluted with 10.0µL 1.8% Saline so
that the drug mixture contained 8.0 µg WAY-100635 per 1.0 µl .9% Saline. Aliquots
were further diluted to achieve appropriate drug concentrations (8.0µg/µl, 0.8µg/µl and
0.08µg/µl). Vehicle treatments consisted of equivolume 0.9% Saline. Rats were
assigned to one of the four treatments prior to behavioral testing and received 0.5µl of
solution per side. The resulting drug amounts infused into the BNST were 4.0µg/0.5µl
WAY, 0.4µg/0.5µl WAY, 0.04µg/0.5µl WAY or 0.5µl vehicle.
For drug infusions, subjects were removed from their cages and handheld in a
towel. The dummy cannulae were removed from guide cannulae and the rats were
injected by hand, one side at a time, through the guide cannulae aimed at the BNST. The
entire infusion process took an average of 5 minutes per rat. Infusions were made
through 28-gauge stainless steel tubing (Plastics One, Roanoke, VA) connected to 10.0 L
Hamilton syringe through PE-50 tubing (Plastics One, Roanoke, VA). The injector
extended 1.0mm beyond the tip of the guide cannula, into the BNST. The injector was
left within the guide cannula for approximately 1 minute to allow for drug diffusion.
Specific Procedures
Experiment 1: WAY-100635 Dose Response within Social Interaction. 64 male
Sprague-Dawley rats were given bilateral cannulations of the BNST as described above.
After being allowed to rest for one week, during which time rats were handled to
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habituate them to injection procedures, pairs of animals were randomly assigned to one of
four drug treatment groups (4.0 g/0.5 l WAY, 0.4 g/0.5 l WAY, 0.04 g/0.5 l WAY,
or vehicle). On the test day, two animals were removed from colony room and
transported within their home cage to the test room and allowed to rest for 5 minutes.
Subjects were removed from their cages and administered assigned treatment as
described above.
Following injections, animals were left to rest in their “displaced” home cage for
5 minutes and then transferred to the conditioning chamber for an acclimation period of 5
minutes. Both subjects then received two 1 mA shocks for 5 seconds each separated by 1
minute and left for a period of 15 minutes within the conditioning chamber. The
parameters for this shock procedure is based off previous work by Amat and colleagues
(1998a, 1998b) who demonstrated that administration of two consecutive shock increases
5-HT release in projection regions of the dorsal raphe nucleus over a 120 minute period
of time.
Rats were then removed from conditioning chamber and transferred to the social
interaction box. Subjects were placed on opposite corners and the remaining 10 minutes
of testing were recorded with a camera. Following the interaction testing, the animals
were removed from the social interaction box and returned to their home cages.
Perfusions and histological verification of cannulae placements were subsequently
conducted as described above to determine whether proper placement was achieved.
Videos were scored by a blinded rater for the amount of time that animals spent in
active social interaction and locomotor activity. Social interaction and locomotor activity
were operationalized through including following, sniffing, boxing, and grooming (see
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File et al., 1978) and total number of line crosses, respectively. Based on a previous
study, anxiety levels were defined as the amount of social interaction per line cross, with
higher ratios indicative of lower levels of anxiety. Pairs of animals were treated as an
n=1 so as to eliminate inflation. Prior to data analysis, data was cleaned and screened for
outliers. A data point was considered an outlier and eliminated from analysis if it was
more than two-standard deviations from the mean. Pairs of animals that contained a rat
that had a histologically verified off-placed cannula and had received the highest dose of
WAY-100635 were compared through planned contrasts against vehicle treated pairs to
check for drug effects at areas surrounding the BNST. A one-way ANOVA was
conducted for locomotor activity, total amount of social interaction and social interaction
controlling for locomotor activity with planned contrasts performed to analyze
differences between pairs that received vehicle treatment versus those that received
varying doses of WAY-100635. A Person’s correlational analysis was also conducted in
order to determine the relationship between total social interaction and line crosses.
Experiment 2: WAY-100635 Dose Response within Baseline Startle. 38 male
Sprague-Dawley rats were given bilateral cannulations of the BNST as described above.
After being allowed to rest for one week, animals were assigned one of four treatment
groups (4.0 g/0.5 l WAY, 0.4 g/0.5 l WAY, 0.04 g/0.5 l WAY, vehicle) and tested
using the acoustic startle paradigm. The experiment was conducted over a three day
period for each rat. The first two days each consisted of a single 20 minute run of startle
testing. Two days of startle testing were performed before drug treatments in order to
acclimate the rats to the test procedure. As will be discussed later, the second day of
startle testing was used to ensure that startle amplitudes did not differ between treatment
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groups. On the third day each animal was run through another single 20 minute run of
startle testing (baseline), administered their designated drug treatment and then run
through a single 45 minute run of startle testing (test). Rats were then placed back into
their home cages and returned to their colony suite. Perfusions and histological
verification of cannulae placements were subsequently conducted as described above to
determine whether proper placement was achieved.
For each acoustic startle test, rats were placed in the startle chambers in the dark,
and a 60 dB background noise was presented continuously in order to eliminate any noise
competition. During the 5 minute acclimation period, activity levels in the absence of
acoustic startle stimulus presentation were measured every 30 seconds through the same
accelerometer device used to measure startle amplitudes. After the 5 minute acclimation
period, rats were measured for their response to acoustic startle stimuli every 30 sec for
either 15 or 40 minutes (depending on test). In order to avoid habituation, rats were
presented with startle stimuli of 3 different intensities (95 db, 100 db, and 105 db) that
were presented in a pseudorandom order such that all three intensities were presented
within each block of three trials. Upon termination of the program, rats were removed
from the boxes and returned to their home cages and startle boxes were cleaned with soap
and water between sessions to avoid odor transfer between animals.
In order to ensure that drug treatment groups did not systematically differ in
startle levels prior to drug administration; rats were matched into groups. For group
matching, the last 3 minutes of startle amplitudes recorded during the second day of
baseline startle testing were averaged for each rat. Subjects were then assigned into
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treatment groups so that the mean startle amplitudes were approximately the same
between groups.
Acoustic startle amplitude was utilized as an index of anxiety levels. Rats were
screened out that had startle amplitudes that were at the maximum measurement unit
greater than 50% of the time. This was done because “clipping” of data exemplifies rats
that had startle amplitudes that were beyond the range of measurement, therefore it would
be impossible to gain an accurate average of these rats’ startle amplitude.
For each rat, a percent increase in startle amplitude produced by drug infusion
was determined by dividing averages of startle amplitudes obtained for each 3-minute
increment of time during test (after WAY-100635 infusion) by the average startle
amplitude during the last 3-minutes of baseline startle (immediately prior to WAY100635 infusion). A repeated-measures general linear model was used to compare
treatment groups for differences within treatment groups across time, between treatment
groups in average percent increase in startle amplitude produced by drug infusion and the
interaction between treatment and time. A one-way ANOVA and planned contrasts were
used to compare differences between the different WAY-100635 treated and vehicle
treated rats.
For each 3-minute increment of time, there were two trials conducted at each
noise burst intensity (95dB, 100dB, 105dB). A percent increase in startle amplitude for
each intensity produced by drug infusion was determined by dividing startle amplitudes
for each 3-minute increment of time during test (after WAY-100635 infusion) by the
average startle amplitude during the last two trials from baseline (immediately prior to
WAY-100635 infusion) for each noise burst intensity. This data was then analyzed
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through use of a repeated-measures general linear model for each noise burst intensity in
order to compare treatment groups for differences within treatment groups across time
for, between group differences in average percent increases in startle amplitude produced
by drug infusion and the interaction between treatment and time. A one-way ANOVA
and planned contrasts were used to compare differences between the different WAY100635 treatment groups and the vehicle treated group.
To ensure that drug effects were due to changes in anxiety and not changes in
overall activity (locomotor changes), activity levels were also analyzed for each treatment
group. Similar to previous analyses, changes in activity levels were determined through
taking the average of the last three minutes of activity during baseline and dividing it out
of averaged 3-minute activity test segments, resulting in a percentage increase in activity
due to treatment. A repeated measures general linear model was run to compare groups
for differences within treatment groups across time, between treatment groups for
average percentage increase from baseline and the interaction between treatment and
time. A one-way ANOVA and planned contrasts were used to compare differences
between the different WAY-100635 treatment groups and the vehicle treated group. A
Person’s correlational analysis was also conducted in order to determine the relationship
between activity levels and startle amplitudes. Further analysis was also conducted
through use of a one-way ANOVA and ANCOVA in order to ensure that changes in
startle were not due to differences in startle box location.
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Results
Histology
Once rats had been perfused and brains were postfixed in Formalin 10% or
Paraformaldehyde 4% and representative slices of cannulations were kept for Cresyl
Violet staining and verification. The area of interest for the current studies was the dorsal
lateral BNST. Cannulations were included in analysis if they were between 0.20 mm and
0.92 mm behind Bregma and fell within the borders of medial, lateral and dorsal portions
of the BNST and the ventral border of the parastrial nucleus. Figure 1 and Figure 3 are
representative illustration of those cannulations that were considered hits for social
interaction and startle respectively.
Because pairs of animals were treated as one score in social interaction testing, a
missed cannulation in one of the animals in the pair resulted in the pair being eliminated
from analysis. A total of five rats (five pairs) were determined to be misses during
histological verification. Two pairs of animals were eliminated from analysis, however
three pairs that were deemed misses and had also received an infusion of 4.0 g/0.5 L
were analyzed as another treatment group in order to examine whether drug effects were
due to spread to surrounding areas. None of the rats tested within the startle testing were
considered to be misses.
Social Interaction Testing
As described above, the effect of drug treatment on locomotor activity, social
interaction and social interaction controlling for locomotor activity were determined.
One pair of animals was removed as an outlier (more than two-standard deviations from
the mean) and, as previously stated, two pairs were eliminated that were determined to be
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missed BNST cannulations and had not received 4.0 g/0.5 l. An additional 4 pairs were
eliminated from analysis due to errors made while conducting the experiment procedure.
The resulting group numbers can be found in Table 1.
Locomotor activity tended to increase dose dependently, however this difference
did not achieve significance F(4,25)= 1.011, p=.424 (Figure 2b). Conversely social
interaction tended to decrease dose dependently, however these differences were also not
significant between treatment groups F(4, 25)= 2.124, p=.114 (Figure 2c). Although
there was no significant difference in activity levels or total social interaction between
groups, Pearson’s correlational analysis showed that these factors were significantly
related to each other such that increases in locomotor activity were related to increases in
social interaction r(21)= .444, p<.05.
Because social interaction correlated with locomotor activity, and based on
previous studies examining social interaction (Short & Maier, 1993), social interaction
was determined by examining the amount of social interaction per line cross. A
significant dose-dependent decrease is social interaction scores was achieved F(4,25)=
3.156, p<.05 (Figure 2a). A significant decrease in social interaction per unit activity was
found for rats treated with 4.0µg/0.5µl in comparison to vehicle treated rats t(21)=2.269,
p<.05; demonstrative of an anxiogenic effect of intra-BNST 5-HT1A antagonism.
Due to the efficacy of the highest dose (4.0µg/0.5µl) of the antagonist in
increasing anxiety levels as measured through social interaction, analyses were conducted
simultaneously to evaluate drug effects of this dose on rats whose cannulae were
implanted outside of the BNST (Figure 3). There was no significant differences found in
planned contrasts between this group of animals and vehicle treated animals on any of the
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behavioral indices. Therefore these results suggest that the anxiogenic effect found
following treatment with 4.0µg/0.5µl dose of WAY-100635 was not due to effects at an
area neighboring the BNST.
Acoustic Startle Test
The effect of 5-HT1A antagonism on startle was determined by examining the
percent increase in startle from baseline to test across time, increase in startle to the
different noise burst intensities from baseline to test, as well as the relation between
startle amplitude and activity. One rat was removed from analysis due to clipping (startle
amplitudes beyond the range of measurement) of data for more than 50% of the test trials.
The resulting group numbers can be found on Table 1. Due to programming errors, the
last 10 minutes of the 40 minute run contained blocks of three trials that did not contain
all three intensities and were presented with intertrial intervals of 10 or 20 sec. This error
in programming resulted in exclusion of this time period from further analysis and use of
the first 30 minutes of startle responses to noise bursts.
Activity levels, determined by pre-noise burst deflections of the accelerometer,
were analyzed in order to ensure that changes in startle amplitudes were not due to
changes in activity due to drug effects. Activity averages and percent changes for each
treatment group were compared against startle effects during the respective time interval.
A repeated-measures analysis demonstrated that there was an effect of drug treatment on
activity levels F(3,33)= 12.637, p<.05. A planned contrast indicated that the lowest dose
of WAY-100635 (0.04 µg/0.5µl) increased activity levels in comparison to vehicle
treated animals t(33)=.227, p<.05 (Figure 4). These results suggest that the drug is
having an effect on activity; these activity changes may be influencing subsequent startle
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levels. A Pearson’s correlational analysis demonstrated that there was no significant
correlation between activity and startle amplitude or the change in activity levels and
change in startle amplitude from baseline to test. The lack of relationship between
activity and startle amplitudes leads to the conclusion that the effect of drug treatment on
activity levels is independent of any effect on startle amplitude. Therefore, no additional
analyses were conducted examining the role that the drug had on activity in affecting
startle amplitude.
Startle changes were calculated as a percentage increase from baseline
(immediately prior to infusion) to test (immediately following infusion) and were
analyzed through examining differences within treatment group effects of time, between
treatment groups and the interaction of treatment and time. A repeated-measures
ANOVA demonstrated that there was a significant within subjects effect of time F(9,
297)= 2.497, p<.05. However there was no significant between group effect of drug
treatment or interaction effect of drug treatment across time (Figure 5b). Therefore these
results indicate that blockade of the 5-HT1A receptor within the BNST had no effect on
anxiety as measured by startle.
In order to examine if startle differed for the groups at particular noise burst
intensities, change in startle from baseline to test was examined for each intensity. There
were no significant differences across time, between drug treatment groups or for the
interaction between treatment group and time for startle in response to a 95 dB or 100dB
noise burst (Figure 6a & 6b). There was a significant effect across time for change in
startle in response to the 105dB noise burst F(9, 297)= 3.904, p<.05, but similar to the
other noise intensities there was no significant difference between drug groups or
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between groups across time on change in startle amplitude in response to the 105dB noise
burst (Figure 6c). An analysis of covariance (ANCOVA) was also performed in order to
determine if location of the startle boxes were influencing any differences in startle
between the treatment groups. There was no effect of box placement on change in startle
amplitude, further demonstrating that effects were not due to equipment effects. Finally,
an analysis was conducted in order to verify that there were no significant differences in
baseline (prior to infusion) startle between treatment groups. A one-way ANOVA
demonstrated that there were no significant differences between treatment groups in their
average baseline startle. These results further support that blockade of the 5-HT1A
receptor within the BNST has no effect on anxiety as measured through startle.
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Discussion
The current set of experiments found that blockade of the 5-HT1A receptor within
the BNST modulated anxiety-like behavior. WAY-100635 dose-dependently decreased
social interaction, which was indicative of an anxiogenic effect. Similar doses of WAY100635 did not effect on baseline startle. These data suggest that the modulation of
BNST 5-HT1A activity modulates anxiety-like behavior, although some differences
between these two paradigms (social interaction and acoustic startle responding) are
apparent.
Anxiety is the most prevalent of all psychological disorders and has been
extensively studied; however the neurobiological underpinnings are still poorly
understood. As mentioned above, previous evidence suggests that the BNST serves as an
interface between some anxiogenic stimuli and behavioral responses. The BNST
receives input from the caudal DRN (Commons et al., 2003), BLA (Dong et al., 2001a;
Dong et al., 2001b) and CeA (Dong et al., 2001a; Dong et al., 2001b), which all have
been shown to mediate fear and anxiety-like behaviors. Consistent with an anxiogenic
role of BNST activation, the BNST projects to areas that mediate specific anxietyassociated behavioral responses such as the nucleus reticularis pontis caudalis and central
grey, which mediate startle responding and social interaction, respectively (for review,
see Walker et al., 2003). Changes in BNST activity modulates many anxiety-like
behaviors including those associated with learned helplessness (Hammack et al., 2004),
light-enhanced startle (Grillon et al., 1997), social defeat (Martinez et al., 1998; Chung et
al., 1999) and long-duration conditioned fear-like responding (Waddell et al., 2006).
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As noted above, the activation of 5-HT systems has been shown to increase and
decrease anxiety-like behavior depending on whether activation is chronic or acute
(Handley, 1995; Grillon et al., 2007), the brain region in which 5-HT is modulated
(Sommer et al., 2001; Andrade et al., 2001) and the 5-HT receptor subtype targeted
(Uphouse, 1997; Lanfumey, 2004). The 5-HT1A receptor has been the most widely
studied in mediating the effects of serotonin activation on anxiety-like behavior. Despite
this attention, few studies have examined the role of the 5-HT1A receptor activation
within the BNST in mediating anxiety-like behavior. One report demonstrated that the
activation of this 5-HT receptor subtype within the BNST might promote an anxiolytic
response within the acoustic startle paradigm (Levita et al., 2004); however, the agonist
used in this study, 5-carboxyamidotryptomine, also binds with similar affinity to 5-HT7
receptors, which are also found in the BNST. The 5-HT7 receptors are G-protein linked
excitatory receptors; activation of which would promote an opposing effect to the 5HT1A receptor (Uphouse, 1997). By blocking the 5-HT1A receptor with antagonist
WAY-100635, which is much more selective to 5-HT1A receptors than 5-CT, the current
studies sought determine if the anxiolytic effect found in the Levita et al., 2004 study was
driven through activation of the 5-HT1A or 5-HT7 receptors within the BNST. An
anxiogenic effect of WAY-100635 in social interaction testing was consistent with prior
data suggesting that activation of the 5-HT1A receptor mediates an anxiolytic response.
The Effect of BNST 5-HT1A Antagonism on Social Interaction
WAY-100635 infusion into the BNST produced a dose dependent decrease in
social interaction per line cross, with the highest dose (4.0µg/0.5µl) of WAY-100635
promoting the greatest anxiogenic effect. The dose-dependency of WAY-100635 is
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consistent with an action at 5-HT1A receptors. Within this behavioral paradigm,
locomotor activity (line crosses) and total amount of social interaction (following,
sniffing, grooming, etc.) were significantly correlated to each other such that higher
amounts of activity were associated with higher amounts of social interaction, although
the antagonist did not significantly alter either measure independently. The lack of a
significant difference between treatment groups on activity levels suggests that the
anxiogenic effect of 4.0µg/0.5µl WAY-100635 on social interaction was not mediated by
drug induced changes in activity. It is important that social interaction scores from rats
with cannulae accidentally implanted outside of the BNST and treated with the highest
WAY-100635 dose were not different from control rats because it supports that the site of
action for WAY-100635 was the BNST and not a neighboring area.
As a 5-HT1A antagonist, WAY-100635 would not alter neuronal excitability
unless an agonist, such as endogenous 5-HT, is activating the 5-HT1A receptor. Hence,
following WAY-100635 infusion, rats were administered two consecutive shocks
because previous studies showed that this treatment was sufficient to induce serotonergic
release in anxiety-related brain areas (Amat et al., 1998a; Amat et al., 1998b). The
anxiogenic effect of 5-HT1A blockade within the BNST following shock suggests that
activation of the 5-HT1A receptor would promote an anxiolytic effect; supporting the
previous results by Levita and colleagues (2004). The dose dependent anxiogenic effect
of WAY-100635 suggests that the highest dose is required in order to achieve maximal
antagonism of the 5-HT1A receptors within the BNST. The reduced efficacy of the
lower doses may have occurred due to lack of maximal 5-HT1A receptor binding;
allowing some serotonin to bind to 5-HT1A receptors.
38

The Effect of BNST 5-HT1A Antagonism on Acoustic Startle
In contrast to the effects found within social interaction, WAY 100635 did not
alter acoustic startle responding. Similar to the social interaction analyses, a significant
effect of drug on activity could suggest that changes in startle amplitude were due to
effects on motor systems. A significant increase in activity was found for the lowest
WAY-100635 dose (0.04µg/0.5µl). A correlation was performed to see if activity levels
were related to startle amplitudes; however, no significant relation was found. The lack
of correlation between these two behavioral indices indicates that the startle amplitudes
performed by the animals following drug infusion were likely not due to drug-induced
changes in activity.
Baseline (pre-infusion) startle differences between groups were eliminated by
matching rats into treatment groups based on their second day of startle testing so that the
average of the last 3 minutes of startle amplitudes did not significantly differ. This
matching procedure was conducted prior to drug infusions in order to ensure that there
were no differences between treatment groups that would mask or potentiate the drug
effects of WAY-100635. A one-way ANOVA, further demonstrated that there were no
significant differences between treatment groups in their baseline (pre-infusion) startle
amplitudes, which may have otherwise influenced test (post-infusion) startle amplitudes.
An analysis of covariance (ANCOVA) was performed in order to determine if the
changes observed in startle from baseline (pre-infusion) to test (post-infusion) varied
across the different test chambers. This analysis was conducted to ensure that the
experimental contexts did not differ and that differences in equipment did not affect the
results. No significant difference was found for an effect of testing chambers on changes
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in startle response. Separate analyses were also performed to examine if changes in
startle amplitude were different for each of the three different noise intensities. Startle
amplitudes in response to the highest noise burst intensity (105dB) decreased slightly
across time, but there were no differences between treatment groups in startle amplitudes
at any noise burst intensity as evidenced by a lack of a significant interaction between
time and treatment group. Hence, the lack of effect of WAY-100635 was not influenced
by drug induced changes in activity levels, particular noise intensity or equipment
confound.
The Role of 5-HT1A Receptors in Anxiety
Most studies suggest that pharmacological activation of 5-HT1A receptors using
agonists such as 8-OH-DPAT, buspirone, ipsapirone and gepirone, have anxiolytic
behavioral effects (Dekeyne, Brocco, Adhumeau, Gobert & Millan, 2000; Stanhope &
Dourish, 1996; Heiser & Wilcox, 1998), which has also been observed in rodents and
humans, and drugs such as Buspirone are prescribed for the treatment of anxiety
disorders (for review, see Heiser et al., 1998). Treatment with 8-OH-DPAT, a commonly
used 5-HT1A agonist, has been shown to have anxiolytic properties in rat. For example
8-OH-DPAT increased punished responding within the Vogel conflict paradigm when
administered systemically (Dekeyne et al., 2000). Conditioned suppression of lever
pressing within the conditioned emotional response test was also decreased in rats after
systemic treatment with the 5-HT1A agonists ipsapirone and gepirone (Stanhope et al.,
1996). Moreover, the anxiolytic effects on the conditioned emotional response test and
Vogel conflict paradigm were blocked through pretreatment with WAY-100635, the 5HT1A antagonist used in the present studies (Dekeyne et al., 2000; Stanhope et al.,
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1996). The anxiogenic effect of WAY-100635 on social interaction reported here is
consistent with the literature reporting anxiolytic responses to systemic injections of 5HT1A agonists, although the lack of effect of WAY-100635 on startle is not consistent
with this literature. Possible reasons explaining the difference in anxiety effects of
WAY-100635 on social interaction and startle will be examined later in discussion.
Although several studies have reported effects of 5-HT1A manipulations on social
interaction in rodents (see below), fewer have investigated the effects of serotonergic
manipulation on acoustic startle. Systemic injection of 8-OH-DPAT or the 5-HT2
receptor agonist, mescaline, has been shown to increase startle, indicative of an
anxiogenic effect (Nanry & Tilson, 1988; Davis, 1987). However, the site of action of
these compounds in the modulation of anxiety-like behavior is not known. For example,
systemic administration of serotonergic drugs may modulate spinal serotonin receptors
altering the startle response directly, rather than changing an underlying anxiety-like state
(Davis et al., 1980). Importantly, in the current study, WAY-100635 was injected
directly into the BNST and hence would be unable to affect serotonin receptors at distal
sites such as the spinal cord. Moreover, no relation was observed between changes in
activity and changes in startle, and, no changes in activity were found in the social
interaction experiment. Hence, it is likely that any effect of WAY-100635 on startle
would have been indicative of modulation an underlying anxiety state, rather than motor
systems.
The Role of 5-HT1A Receptor in Social Interaction
Previous studies have examined the role of 5-HT1A receptor
activation/inactivation in the modulation of social interaction using both systemic
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injections and brain infusions of 5-HT1A agonists and antagonists. Systemic
administration of 5-HT1A agonists such as 8-OH-DPAT usually increased social
interaction, which is indicative of an anxiolytic effect (Dekeyne et al., 2000; Picazo,
Lopez-Rubalcava, Fernandez-Guasti, 1995), and typically these effects were blocked by
the pretreatment of WAY-100635 (Dekeyne et al., 2000). These findings are consistent
with the anxiogenic effect observed after administration of the 5-HT1A antagonist within
social interaction in the current study. As mentioned above, the brain region mediating
the effects of systemically administered serotonergic drugs on anxiety is unknown,
although our current studies suggest that the BNST may be a critical site of action for
these effects.
Other studies in which 5-HT1A agents were injected into discrete brain regions,
found different effects on social interaction depending on the region targeted. Intramedian raphe nucleus administration of 5-HT1A agonist 8-OH-DPAT has led to
increases in social interaction due to activation of MRN 5-HT1A receptors and inhibition
of MRN activity (Andrews, Hogg, Gonzalez & File, 1994; File, Gonzalez & Andrews,
1996). Lesions made to the DRN serotonergic neurons blocked the anxiolytic effects of
systemic 5-HT1A agonistic effects within social interaction (Picazo et al., 1995).
Interestingly, 5-HT1A agonist treatments aimed at projection regions of the MRN and
DRN, such as the basolateral amygdala and the hippocampus, have found anxiogenic
effects on social interaction (Andrews et al., 1994; File et al., 1996; Gonzalez, Andrews
& File, 1996). Although not addressed in the current set of experiments, the basolateral
amygdala and hippocampus are other brain regions that receive 5-HT input from the
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DRN and MRN and hence may be other sites by which 5-HT might modulate
fear/anxiety-like behavior.
Few studies have examined the effect of 5-HT1A drugs within the BNST. 5HT1A receptors can be located either a pre-or post-synaptically. For example, activation
of somatodendritic presynaptic 5-HT1A autoreceptors within the DRN produces a well
known reduction in 5-HT production and 5-HT release from terminals. In addition, postsynaptic 5-HT1A receptor activation also leads to an inhibitory effect on neuronal firing
in projection regions of the raphe nuclei (Uphouse, 1997). Systemically administered 5HT1A agonists and antagonists likely act at both pre- and/or postsynaptic 5-HT1A
receptors; hence, it is difficult to determine the site of action for behavioral changes
produced by drugs administered in this manner. The previously described results suggest
that activation of presynaptic receptors within the MRN and DRN is anxiolytic.
Interestingly, 5-HT1A-induced decreased DRN serotonin activity may still modulate
anxiety-like behavior via action at postsynaptic 5-HT1A receptors in the BNST.
Whereas high levels of BNST serotonin likely bind to several 5-HT receptor subtypes
that increase and decrease BNST activity, lower levels of circulating serotonin within the
BNST may preferentially act at postsynaptic 5-HT1A receptors, which inhibit BNST
neuronal activity to produce less anxiety. The anxiogenic effects of WAY-100635 on
social interaction are consistent with an anxiolytic role for the activation of postsynaptic
BNST 5-HT1A receptors.
Different Effects of BNST 5-HT1A Antagonism on Social Interaction & Acoustic Startle
These studies found differential effects of BNST 5-HT1A antagonism on social
interaction and the baseline acoustic startle response. While the acoustic startle response
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is a reflexive measurement of the current emotional state, social interaction measures
changes in emotional state through use of an approach/avoidant paradigm which
incorporates uncertainty about the novel environment and also introduces a social
component (Handley, 1995; File et al., 1978). One goal of this study was to determine if
the 5-HT1A receptor had the same functional properties across these two different of
anxiety measures. The difference in findings between these two studies may be due to a
different role of 5-HT or the BNST in modulating these behaviors. However, Levita et
al. (2004) demonstrated an anxiolytic effect of BNST 5-HT manipulation on the startle
paradigm, which was consistent with the anxiogenic effect on social interaction by
blockade of the 5-HT1A receptor.
Another explanation for the different effects observed between these two
experiments is that two difference procedures were employed. For the social interaction
test, two-consecutive shocks were given after administration of the 5-HT1A antagonist,
which were not administered before testing the startle response. Shock was not
administered during startle testing because pilot data demonstrated that WAY-100635
modulated startle in the absence of shock, which suggested that the BNST contained
endogenous circulating 5-HT in this testing paradigm.
As previously discussed, both the 5-HT2 and 5-HT7 receptors are also located
within the BNST. 5-HT has the highest affinity for the 5-HT1A and 5-HT7 receptors,
followed by the 5-HT2 (Palacios et al., 1996). Because WAY-100635, as an antagonist,
does not have any action other than blocking 5-HT1A receptors, it is likely that the
anxiogenic effect of WAY-100635 on social interaction was achieved due to the
activation of both the 5-HT2 and 5-HT7 receptors by high levels of endogenous
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circulating 5-HT following administration of shock. Therefore, social interaction testing
was most likely influenced by the activation of both the 5-HT7 and 5-HT2 receptors due
to high levels of endogenous 5-HT release. The lack of shock administration prior to
startle testing and the habituation procedure that was employed the two days prior to drug
infusion testing most likely resulted in a lower amount of endogenous 5-HT release.
Therefore, the low levels of endogenous 5-HT may have activated the 5-HT7 and/or 5HT2 receptors at such a low amount that the behavioral effect could not be detected.
While activation of both 5-HT2 and 5-HT7 receptors is excitatory, they could be
differentially located on interneurons and/or projection neurons and/or result in the
release of various neuropeptides such as GABA, CRF, neuropeptide Y, enkephalin or
neurotensin (Ju et al., 1989; Sun & Cassell, 1993; Vienante et al., 1997; Phelix et al.,
1992; Peto et al., 1999; Day et al., 1999). Therefore, the postsynaptic location of the 5HT2 or 5-HT7 receptors could result in release of excitatory or inhibitory neuropeptides.
The behavioral response is ultimately dependent on the net result of integration of these
different excitatory and inhibitory inputs and projections.
Recent evidence has suggested that WAY-100635 may be an agonist at the
dopamine 2, 3 and 4 (D2, D3, D4) receptor subtypes (Chemel, Roth, Arbruster, Watts &
Nichols, 2006). Initially, Forster et al. (1995) reported that WAY-100635 was 100 times
more selective for the 5-HT1A receptor subtype than for the D2 and D4 receptor
subtypes. However this has been refuted by Chemel and colleagues (2006) who found
that WAY-100635 was only 10 times more selective for the 5-HT1A receptor subtype
than the D4 receptor, but more than 100 times more selective for the D2 and D3 receptor
subtypes. Postmortem in situ hybridization studies in humans show that the area of the
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BNST highly expresses D1 and D2 mRNA (Hurd, Suzuki & Sedvall, 2001). However,
autoradiography studies have failed to find evidence for D4 receptors to be localized
within the BNST within rats (Primus, Thurkauf, Xu, Yevich, McInerney, Shaw, Tallman
& Gallagher, 1997). Because of the low affinity of binding to the D2 receptor within the
BNST and the lack of D4 receptor localization within this area, it is unlikely that the
effects of WAY-100635 observed in the current studies were mediated by DA receptor
binding.
Limitations and Conclusions
While the preceding results suggest a role for 5-HT1A receptors within the BNST
in modulation of anxiety, there are some limitations. The lack of consistency between
paradigms raises some concerns. It is unclear if the different effects found within the two
studies were due to differences in endogenous circulating serotonin, differences in the
type of anxiety being measured, a combination of both, or some other variable.
Additional studies are ongoing in order to investigate if 5-HT1A antagonism would be
anxiogenic if rats were administered two consecutive shocks prior to being tested for
acoustic startle, although these studies are beyond the scope of this paper.
The target area within the current studies was the anterolateral region of the
BNST due to its importance in modulating anxiety-like behavior as demonstrated through
stimulation, neurochemical and anatomical data (Casada & Daphne, 1991; Phelix et al.,
1992; Alheid et al., 1995). While the majority of neurons within this area are
GABAergic (Cullinan, Herman, & Watson, 1993; Erlander, Tillakartne, Feldblum, Patel,
& Tobin, 1991), these neurons may also release other neuropeptides such as CRF,
enkephalin, CCK, neurotensin, neuropeptide Y and others that may or may not inhibit
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postsynaptic sites. Therefore, activation of 5-HT1A receptors within the BNST may
inhibit the firing of neurons that carry excitatory and inhibitory receptors adding
complexity to the mechanism through which the BNST modulates anxiety-like behavior.
While this complexity exists, the current results and the effects found by Levita and
colleagues (2004) suggest that activation of this anterolateral region of the BNST seems
to increase anxiety-like behavior.
The current results suggest an anxiolytic action of the 5-HT1A receptor activation
within the BNST, however there are at least three other functional serotonin receptors
within this area (Singewald et al., 2003; Levita et al., 2004; Fox, Hammack, & Falls, in
press). As previously discussed, these receptors may be located on various types of
neurons and the ratios of these activated receptors may have differed between the current
behavioral paradigms. Because of the lack of knowledge for the role of the activation of
other 5-HT receptor subtypes within the BNST on anxiety-like behavior, it is unknown
which receptor/s mediated the behavioral effects observed following BNST 5-HT1A
antagonism. Future studies focusing on the role of these receptors and the interaction
between the various receptors within the BNST will help to better understand the role that
serotonin in the BNST plays in anxiety.
While the two current studies yielded different results, the known serotonergic
release during the social interaction experiment and the previous results found by Levita
et al. (2004) suggest that inhibition within the BNST via the activation of the 5-HT1A
receptor is effective in reducing anxiety states. These studies provide insight to possible
targets of future pharmacotherapies and how those that target the 5-HT1A receptor
subtype may be beneficial in reducing anxiety.
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Figure & Table Captions
Table 1. Group numbers for social interaction and startle testing, including animals not
used for statistical analysis.
Figure 1. A schematic representation of BNST guide cannulae placement for social
interaction testing. Points represent the injector tip for animals receiving varying doses
of WAY-100635. X’s represent those animals that were considered misses and also
included in analysis. Coronal sections are shown from -0.20 through -0.92mm relative to
bregma.
Figure 2. Figure 2a- Treatment with WAY-100635 dose dependently decreased the
amount of social interaction per unit of activity with 4.0µg/0.5µl promoting an
anxiogenic effect. Figure 2b- Locomotor activity was defined in terms of line crosses
made during a 10 minute period by the animals paired during social interaction; no
significant differences were found. Figure 2c- Total amount of social interaction
(sniffing, grooming, boxing, etc.) measured over a 10 minute period. 5-HT1A receptor
antagonism within the BNST or neighboring brain areas did not affect locomotor activity.
WAY-100635 doses: 4.0 g/0.5 l, 0.4 g/0.5 l, 0.04 g/0.5 l, vehicle.
*p<0.05 with respect to vehicle treated group.
Figure 3. A schematic representation of BNST guide cannulae placement for startle
testing. Points represent the injector tip for animals receiving varying doses of WAY100635. Coronal sections are shown from -0.20 through -0.80mm relative to bregma.
Figure 4. Intra-BNST blockade of 5-HT1A receptors increased activity during acoustic
startle testing. Rats treated with 0.4 g/0.5 l WAY-100635 demonstrated an increase in
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activity in comparison to vehicle treated rats. *p<0.05 with respect to vehicle treated
group.
Figure 5. Figure 5a- No significant effect was found for treatment groups on percentage
increase in startle from pre-infusion to post-infusion testing. Figure 5b- Average
percentage increase across time in startle amplitudes from pre-infusion to post-infusion
testing. The percentage increase in startle amplitude diminished over time.
WAY-100635 doses: 4.0 g/0.5 l, 0.4 g/0.5 l, 0.04 g/0.5 l, vehicle
Figure 6. Figure 6a- No significant effect was found for treatment groups on percentage
increase in startle amplitude from pre-infusion to post-infusion testing in response to
95dB noise bursts. Figure 6b- No significant effect was found for treatment groups on
percentage increase in startle amplitude from pre-infusion to post-infusion testing in
response to 100dB noise bursts. Figure 6c- A significant effect was found across time
such that there was a decrease in percent change as time progressed.
WAY-100635 doses: 4.0 g/0.5 l, 0.4 g/0.5 l, 0.04 g/0.5 l, vehicle
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Table 1
VEHICLE 0.04µg/0.5µl 0.4µg/0.5µl 4.0µg/0.5µl
Social
Interaction
N= 26
Baseline
Acoustic
Startle
N= 27

6

6

5

6

10

8

10

9
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Miss
Excluded
From
4.0µg/0.5µl
Analysis
3
7
N/A

1

Figure 1

bregma -0.22 mm

bregma -0.26 mm

bregma -0.30 mm

bregma -0.40 mm

x
bregma -0.80 mm
x x

bregma -0.92 mm
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Figure 2
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Figure 3

bregma -0.22

bregma -0.26
mm

bregma -0.30

bregma -0.40

bregma -0.80

68

Figure 4
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Figure 5
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Figure 6
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